Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label Study Of T138067-Sodium In A Second-Line Setting In Non-Small-Cell Lung Cancer Patients With Locally Advanced Or Metastatic Disease Who Have Failed First-Line Therapy With a Taxane

NCT00022243 is registered in ClinicalTrials.gov with Tularik as lead sponsor.

NCT NCT00022243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00022243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label Study Of T138067-Sodium In A Second-Line Setting In Non-Small-Cell Lung Cancer Patients With Locally Advanced Or Metastatic Disease Who Have Failed First-Line Therapy With a Taxane
Lead sponsor
Tularik
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2000
Completion date
Not reported
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer